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A series of coumarin and pyranocoumarin analogues were evaluated in vitro for antiviral efficacy against measles virus (MV), strain Chicago. Of
the 22 compounds tested for inhibition, six were
found to have selectivity indices greater than 10.
These were compounds 5-hydroxy-7-propionyloxy-4-propylcoumarin (2a), 5,7-bis(tosyloxy)-4propylcoumarin (7); 5-hydroxy-4-propyl-7-tosyloxy-coumarin (8); 6,6-dimethyl-9-propionyloxy-4propyl-2H,6H-benzo[1,2-b:3,4-b′]dipyran-2-one
(9); 6,6-dimethyl-9-pivaloyloxy-4-propyl-2H,6Hbenzo[1,2-b:3,4-b′]dipyran-2-one (10); and 7,8-cis10,11,12-trans-4-propyl-6,6,10,11-tetramethyl7,8,9-trihydroxy-2H,6H,12H-benzo[1,2-b:3,4-b′:5,6b′′]tripyran-2-one (18). Three of the active drugs
were propyl coumarin analogues (2a, 7 and 8),
two were dipyranone or chromeno-coumarins (9
and 10), and one was a benzotripyranone with a
coumarin nucleus (18). Some appeared to be
rather specific and potent inhibitors of MV with
EC50 values ranging from 0.2 to 50 µg/ml and the
majority of the EC50 values being less than
5 µg/ml. The compounds inhibited an additional

nine strains of MV, and in virucidal tests the drugs
did not physically disrupt the virion to inhibit virus
replication. The inhibitory activity for one of the
compounds tested (7) was somewhat dependent
on virus concentration and it was still active when
added to cells up to 24 h after virus exposure.
When used in combination with ribavirin, compound 7 appeared not to profoundly affect the
antiviral efficacy of ribavirin or its cell-associated
toxicity. However, a slightly antagonistic MVinhibitory effect was observed at the highest concentration of ribavirin used in combination with
most concentrations of compound 7 tested. This
and related compounds may be valuable leads in
the development of a potent and selective class of
MV inhibitors that could be used in future in the
clinic.
Keywords: coumarin, pyranocoumarin, benzodipyranone, benzotripyranone, measles virus,
inhibition, antiviral, structure–activity relationships

Introduction
Measles virus (MV) is a ubiquitous pathogen that still
ranks as one of the leading causes of infectious diseaseinduced morbidity and mortality in childhood throughout
the world. Currently, 30–40 million measles infections
occur worldwide each year leading to 1–2 million deaths
(Manchester et al., 2000). In addition to causing an acute
respiratory infection, this disease is also associated with a
serious, but transient suppression of cell-mediated immunity (Wyde et al., 2000), apparently mediated by virus proteins resistant to heat treatment (Marttila et al., 2001). This
immunosuppression can lead to secondary infections, and
major complications such as pneumonia and diarrhoea in
children, especially in those suffering from malnutrition
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(Griffin & Bellini, 1996). In rare cases, it can also cause
encephalitis and persistent central nervous system infections (Griffin & Bellini, 1996).
Although the use of a live attenuated virus has nearly
eradicated the endemic circulation of measles in the USA
and in other highly industrialized nations, re-introduction
of the virus can still cause repeated limited outbreaks
(Gay, 2000). In addition, vaccine safety has occasionally
been questioned because of tenuous links to Crohn’s disease
and particularly to autism (Kawashima et al., 2000). No
studies to date, however, have conclusively established a
causal relationship with vaccine viruses and those two diseases (Afzal et al., 2000). Therefore, campaigns need to be
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maintained that establish high routine coverage of the vaccine to prevent the re-accumulation of susceptible hosts
that will permit sustained measles transmission (Gay,
2000). Those who may be especially vulnerable are the nonimmunized or immunized individuals with waning immunity, such as those living in extended care facilities
(Clements & Cutts, 1995). In addition, with an increasing
number of health care professionals having only received
vaccine or never having been exposed to measles infection
in infancy, nosocomially-acquired and -transmitted MV
infections in health care facilities may also contribute to a
potential increase in MV infections (Steingart et al., 1999).
Thus, there always exists the potential for limited measles
outbreaks until indigenous virus transmission is eliminated
in most populations of a given country (reviewed by De
Serres et al., 2000). Furthermore, the efforts for the elimination of measles virus outbreaks is challenged significantly by the fact that measles virus isolates are not of single
genotype or even serotype. As with other RNA viruses,
MV has demonstrated considerable heterogeneity as measured by monoclonal antibody reactivities and nucleotide
sequencing (Rota et al., 1998). The RNA sequences of the
strains of MV currently circulating have changed considerably from those isolated earlier.
Thus, there is a need to supplement global immunization with non-toxic therapeutic agents that can be used to
treat unexpected outbreaks of measles virus infections
quickly and effectively. No chemotherapeutic agents have
yet been approved for treatment of measles virus infections,
although ribavirin has been reported to be efficacious in
patients when administered intravenously and orally alone
(Gururangan et al., 1990) or in combination with immune
serum globulin (Stogner et al., 1993). No other clinical trials have been carried out to support these findings; to the
contrary, a number of studies have shown that ribavirin is
of no obvious clinical efficacy in measles virus infections
when given as small-particle aerosol or intravenously
(reviewed by Wyde et al., 2000). Recently, Barnard et al.
(2001) reported several 5′-norcarbocyclic adenosine analogues that potently and selectively inhibited MV replication in vitro.
Historically, natural products have been a great resource
to find novel and biologically active agents, included
among which are coumarin-type compounds. Naturally
occurring coumarin analogues have been reported to exhibit anti-tumor and antiviral properties (McKee et al., 1996;
Pengsuparp et al., 1999; Semple et al., 1999). These lead
compounds have stimulated interest in the synthesis of
more potent, less toxic analogues targeted to specific viral
functions (Zhao et al., 1997; Martyanov et al., 1999; Yang
et al., 1999). Coumarin compounds have been shown to
inhibit HIV-1 reverse transcriptase (Bourinbaiar et al.,
1993), HIV-1 integrase (Zhao et al., 1997), HIV-1 protease
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(Skulnick et al., 1997), protein kinase C (Yang et al., 1999),
and vaccinia DNA topoisomerase (Sekiguchi et al., 1996)
among other viral targets. In addition, a number of di-substituted (3′R, 4′R)-cis-khellactone analogues with a
coumarin nucleus have been synthesized (Xie et al., 1999).
These derivatives possess potent anti-HIV inhibitory activity involving an as yet unknown mechanism and have been
studied for structure-activity relationships (Xie et al., 2001).
Moreover (+)-calanolide A, one of the coumarin compounds studied in depth, has been evaluated for safety and
pharmacokinetic profiles in healthy human volunteers
(Creagh et al., 2001) and is currently being investigated for
anti-HIV efficacy in HIV-infected volunteers (R Sherer,
CORE Center, Cook County Hospital, Chicago, Ill., personal communication).
Thus, coumarin analogues represent a novel class of
compounds that warrant further investigation as potential
antiviral agents. Herein we wish to present some of the first
data on the anti-MV activity of coumarin and pyranocoumarin analogues.

Materials and methods: chemistry
General
Melting points were uncorrected. Unless otherwise stated,
the 1H NMR and 13C NMR spectra were recorded on a
Varian Gemini 2300 at 300 and 75.5 MHz, respectively, or
a Varian Inova NMR spectrometer at 400 and 100.5 MHz,
in the indicated deuterated solvent with chemical shifts
reported in parts per million (ppm) using tetramethylsilane
as the internal standard. FTIR was performed on a
MIDAC Model M12000 and mass spectra were recorded
on a Finnegan MAT 90 or a Finnegan LCQ-MS spectrometer. TLC analyses were performed on analytical thin
plates coated with silica gel 60 F254 (Merck) and components were visualized under UV or stained with iodine.
Column chromatography was performed using silica gel 60
(70–230 mesh from EM Sciences). Elemental analyses
were carried out at Midwest Microlab (Indianapolis, Ind.,
USA). All commercial reagents and solvents were used
without further purification. Ribavirin, used as a positive
control, was obtained from ICN Pharmaceuticals Inc.
(Costa Mesa, Calif., USA). Compounds 1, 4, 5, 6 and 14
were synthesized by the published procedures (Flavin et al.,
1996) while compounds 7 and 8 prepared according to the
literature method with some modifications. All the compounds reported herein were fully characterized and were
in agreement with the assigned structures.
5-hydroxy-7-propionyloxy-4-propylcoumarin (2a). To a
2 l, three-neck round-bottom flask equipped with a stir bar,
addition funnel and a N2 inlet and outlet were added 50 g
(2.27 mol) of 5,7-dihydroxy-4-propylcoumarin (1)
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(Flavin et al., 1996), 500 ml of anhydrous THF and 1 ml of
pyridine. To this reaction mixture, 33 g (2.27 mol) of propionic anhydride was added dropwise at room temperature
under constant stirring. After 90 min, the reaction was
stopped and reaction mixture washed with 5% aqueous
NaHCO3 solution. The organic layer was separated and
washed with 1 N HCl and brine. The aqueous layers were
extracted with dichloromethane. The organic layers were
combined and washed with brine. The crude product was
dried over Na2SO4, rotary evaporated and concentrated in
vacuo to give 62 g crude product. TLC (1:1 hexane/ethyl
acetate) analysis indicated that the crude material contained the desired product 2a, coumarin (1) and a small
amount of 5,7-diester 3a. The crude product was then
purified by silica gel column chromatography on a Biotage
column by eluting with 2:1 hexane/ethyl acetate and resulted in 12 g of 2a (36% yield) as white solid: melting point:
166–168°C (170–171°C, Flavin et al., 1996); 1H NMR
(DMSO-d6), δ:0.97 (3H, t, J = 7.2 Hz), 1.14 (3H, t, J = 7.4
Hz), 1.62 (2H, sextet, J = 7.5 Hz), 2.62 (2H, q, J = 7.5 Hz),
2.92 (2H, t, J = 7.5 Hz), 6.09 (1H, s), 6.57 (1H, d, J = 2.4
Hz), 6.67 (1H, d, J = 2.4 Hz), 11.10 (1H, s); 13C NMR
(CDCl3) δ: 8.6, 13.7, 22.4, 26.9, 37.2, 101.4, 105.3, 106.2,
111.9, 153.0, 155.9, 157.2, 158.0, 159.7, 172.2; IR (film)
3300-3075, 2968, 1758, 1676, 1610, 1433, 1126 cm–1; MS
m/e 277 (M+1); analysis calculated for C15H16O5: C, 65.21;
H, 5.84. Found: C, 64.61; H, 5.86.
5-hydroxy-7-pivaloyloxy-4-propylcoumarin

(2b).

Pyridine (2.02 ml, 25 mmol) was added to a solution of 1
(1.10 g, 5 mmol) in THF (10 ml) followed by the addition
of pivaloyl chloride (0.612 ml, 5 mmol). The resulting mixture was stirred at room temperature for 6 days. The pyridinium hydrochloride was removed by filtration and the
product washed a few times with ethyl acetate. The organic solutions were combined and washed successively with
1N HCl (2×25 ml), water (25 ml), aqueous saturated
NaHCO3 (25 ml). The product was then dried over
Na2SO4 and concentrated under vacuum, the crude product
was purified by silica gel chromatography (8:1 hexane/ethyl
acetate to 2:1 hexane/ethyl acetate) to obtain 3b (350 mg,
18% yield) and the corresponding monoester 2b (550 mg,
36% yield) as a white solid. The analytical profile of compound 2b was as follows: melting point: 158–160°C; Rf =
0.32 (4:1 hexane/ethyl acetate); 1H NMR (CDCl3) δ: 0.97
(3H, t, J = 7.8 Hz), 1.37 (9H, s), 1.56 (2H, sextet, J = 7.4
Hz), 2.84 (2H, t, J = 7.8 Hz), 6.07 (1H, s), 6.43 (1H, d, J =
2.4 Hz), 6.61 (1H, d, J = 2.1 Hz), 8.09 (1H, s); 13C NMR
(CDCl3) δ: 13.8, 22.4, 26.9, 37.8, 39.3, 102.4, 105.8, 107.2,
112.1, 153.3, 156.2, 156.3, 159.3, 161.9, 178.0; IR (film)
3358, 2971, 2365, 1730, 1615, 1431, 1275, 1146 cm–1; MS
m/e 305 (M+1); analysis calculated for C17H20O5: C, 67.09;
H, 6.62. Found: C, 66.80; H, 6.70.
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5,7-bis(pivaloyloxy)-4-propylcoumarin (3b). Pivaloyl
chloride (0.673 ml, 5.5 mmol) was added to a solution
of 1 (1.10 g, 5 mmol) in pyridine (12 ml) and THF (6 ml)
at 0°C. The mixture was allowed to warm to room temperature and stirred at room temperature for 24 h. TLC indicated the presence of the unreacted 1. In an effort to drive
the reaction to completion, additional pivaloyl chloride
(0.50 ml) was added and the reaction stirred at room temperature for another 72 h. The pyridinium hydrochloride
was removed by filtration and washed a few times with
ethyl acetate. The organic solutions were combined and
washed successively with 1N HCl (2×25 ml), water
(25 ml), and aqueous saturated NaHCO3 (25 ml). The
crude products were dried over Na2SO4 and concentrated
under vacuum, the crude product was purified by silica gel
chromatography (2:1 hexane/ethyl acetate) to obtain 3b as
a white solid (1.90g, 98% yield). Analysis of 3b resulted in
the following data: melting point 110–112°C; Rf = 0.49
(4:1 hexane/ethyl acetate); 1H-NMR (CDCl3) δ: 1.03 (3H,
t, J = 7.8 Hz), 1.36 (9H, s), 1.41 (9H, s), 1.69 (2H, sextet,
J = 7.4 Hz), 2.81 (2H, t, J = 7.8 Hz), 6.22 (1H, s), 6.60 (1H,
d, J = 2.4 Hz), 7.03 (1H, d, J = 2.1 Hz); 13C-NMR (CDCl3)
δ: 13.5, 20.7, 26.4, 26.8, 26.9, 36.4, 39.2, 39.4, 108.6,
111.5, 113.4, 114.2, 149.4, 152.7, 154.9, 155.4, 159.9,
177.1; IR (film) 3090, 2971, 2941, 2876, 1757, 1750, 1615,
1481, 1422, 1273 cm–1; MS m/e 389 (M+1); analysis
calculated for C22H28O6: C, 68.02; H, 7.26. Found: C,
67.77; H, 7.18.
7-TBDMS and 5,7-bis(TBDMS) substituted coumarins
(2c and 3c). A mixture of coumarin 1 (5.0 g, 23 mmol),

TBDMS-Cl (5.8 g, 27 mmol), and imidazole (4.7 g,
69 mmol) in 50 ml of dry DMF was stirred at room temperature under N2 for 20 h, whereupon EtOAc (300 ml)
was added to the reaction mixture. The precipitates formed
were removed by filtration. The filtrate was washed successively with 1N HCl (2×100 ml), water (3×100 ml), and
brine (200 ml). The organic layer was then dried with
Na2SO4. After removal of the drying agent by filtration, the
organic solution was kept at room temperature and crystals
were formed. The solid was collected. The mother liquor
was concentrated and the residue crystallized from
EtOAc. This process was repeated two more times to give
overall 2.2 g (28% yield) of 2c as white crystals. The residue
from the mother liquor was further purified by column
chromatography to give 2.5 g (24% yield) of bis-TBDMS
ether 3c, additional 0.2 g of 2c (a combined yield of 31%),
and 0.2 g of unreacted starting material 1. The analytical
data of 2c were: melting point 220–223°C; 1H NMR
(acetone-d6) δ: 0.28 (6H, s), 1.00 (12H, s), 1.69 (2H, sextet, J = 7.5 Hz), 2.91 (2H, t, J = 7.5 Hz), 5.91 (1H, s), 6.33
(1H, d, J = 2.7 Hz), 6.42 (1H, d, J = 2.4 Hz), 9.55 (1H, s);
1
H NMR (DMSO-d6) δ: 0.20 (3H, s), 0.40 (3H, s), 0.99
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(9H, s), 1.01 (3H, s), 1.63 (2H, sextet, J = 7.5 Hz), 2.95
(2H, t, J = 7.5 Hz), 6.06 (1H, s), 6.26 (1H, d, J = 2.7 Hz),
6.52 (1H, d, J = 2.4 Hz); 13C NMR (DMSO-d6) δ: –4.7,
–3.9, 13.7, 22.4, 25.4, 37.1, 99.2, 103.3, 103.5, 109.8,
156.7, 157.5, 158.4, 158.5, 160.1; IR (film) 3497-3021,
2957, 1684, 1616 cm–1; MS m/e 335 (M+1); Analysis calculated for C18H26O4Si: C, 64.64; H, 7.83. Found: C,
64.31; H, 7.78. For 3c: melting point 78–79°C; 1H NMR
(DMSO-d6) δ: 0.24 (6H, s), 0.36 (6H, s), 0.95–9.97
(21H, m), 1.59 (2H, q, J = 7.5 Hz), 2.91 (2H, t, J = 7.5 Hz),
6.02 (1H, s), 6.21 (1H, d, J = 2.7 Hz), 6.48 (1H, d,
J = 2.4 Hz).
5,7-bis(tosyloxy)-4-propylcoumarin (7). A mixture of 1

(30 g, 0.14 mol), K2CO3 (76 g, 0.55 mol), p-toluenesulfonyl chloride (57 g, 0.3 mol) and acetone (450 ml) was
refluxed for 4.5 h. After cooling to room temperature, the
mixture was filtered and the filtrate evaporated to give a
light-yellow solid. The solid residue was dissolved in a
mixture containing 1.2 l of EtOAc and 1 l of water. The
aqueous layer was removed and extracted with EtOAc
(2×200 ml). The combined organic layers were washed
with brine, dried over Na2SO4, filtered, and then concentrated under vacuum to afford 75 g of crude product as a
light-yellow solid. The crude material was triturated with
EtOAc to remove polar impurities and then filtered to
give a white solid and an orange filtrate. The white solid
was triturated with hexane to remove the less polar impurities and then filtered to give 51.8 g of 7 as a white
powder. The orange filtrate was concentrated to give 22 g
of residue as a dark-orange oil which was solidified by
addition of hexane. The solid was collected by filtration,
triturated with EtOAc, filtered, and washed with hexane to
give an additional 11.7 g of product as a white powder.
A total of 63.5 g (88% yield) of 7 was obtained with the
following characteristics: melting point 110–112°C
(112°C, Fox et al., 2000); 1H NMR (DMSO-d6) δ 0.82
(3H, t, J = 7.2 Hz), 1.44 (2H, sextet, J = 7.5Hz), 2.44
(3H, s), 2.46 (3H, s), 2.72 (2H, t, J = 7.6 Hz), 6.36 (1H, s),
6.80 (1H, d, J = 2.4 Hz), 7.20 (1H, d, J = 2.4 Hz), 7.52
(2H, d, J = 8.4 Hz), 7.54 (2H, d, J = 7.8 Hz), 7.78 (2H, d,
J = 8.4 Hz), 7.80 (2H, d, J = 8.4 Hz); 13C NMR
(DMSO-d6) δ 13.3, 21.2, 21.5, 36.1, 110.1, 111.7, 112.1,
116.3, 128.4, 128.5, 130.7, 130.8, 130.9, 146.3, 146.8,
147.2, 149.8, 154.0, 155.1, 158.2; IR (film) 3094,
2965–2878, 1740, 1615, 1379, 1192 cm-1; MS m/e 529
(M+); analysis calculated for C26H20O8S2: C, 59.08; H, 4.58.
Found: C, 58.97; H, 4.58.
5-Hydroxy-4-propyl-7-tosyloxy-coumarin (8). Sixty

grams (0.113 mol) of the bistosylated compound 7 and
300 ml of THF were added to a 1 l, three-necked roundbottomed flask equipped with a mechanical stirrer, an
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addition funnel, a thermometer, and N2 inlet/outlet. The
solution was cooled to 0°C, and 125 ml (0.125 mol) of a 1.0
M solution of tetra-n-butylammonium fluoride in THF
was added. The mixture was stirred at 0°C for 5 h. The solvent was then removed under vacuum to give a greenbrown oil which was diluted with 1 l of EtOAc and washed
with water (500 ml). The aqueous layer was extracted with
EtOAc (2×250 ml). The organic layers were combined,
washed with brine (300 ml), dried over Na2SO4 and
filtered. The solvent was removed under vacuum to yield
100 g of a thick green-brown oil that was purified by
filtering through a column of silica gel using EtOAc as the
eluent. The EtOAc eluents were concentrated and the
resulting solid was crystallized from EtOAc to afford 24 g
(57% yield) of 8 as a white solid. The analytical data for this
product were: melting point 214–215°C (210°C, Fox et al.,
2000); 1H NMR (DMSO-d6) δ 0.94 (3H, t, J = 7.2 Hz),
1.57 (2H, sextet, J = 7.4 Hz), 2.44 (3H, s), 2.88 (2H, t,
J = 7.5 Hz), 6.11 (1H, s), 6.49 (1H, d, J = 2.4 Hz), 6.55
(1H, d, J = 2.4 Hz), 7.51 (2H, d, J = 8.1 Hz), 7.82 (2H, d,
J = 8.1 Hz), 11.29 (1H, s); 13C NMR (DMSO-d6) δ 13.7,
21.2, 22.3, 37.0, 101.3, 105.0, 107.4, 112.6, 128.4, 130.5,
131.4, 146.3, 150.9, 155.7, 157.5, 157.6, 159.3; IR (film)
3092, 2967, 1692, 1611, 1379 cm-1; MS m/e 375 (M+1);
analysis calculated for C19H18O6S: C, 60.95; H, 4.85.
Found: C, 60.85; H, 4.83.
6,6-Dimethyl-9-propionyloxy-4-propyl-2H,6Hbenzo[1,2-b:3,4-b′]dipyran-2-one (9). (n-Bu)4NI (1.11 g,

3 mmol), K2CO3 (1.04 g, 7.5 mmol), and 3-chloro-3-methyl1-butyne (1.11 g, 3 mmol) were added to a solution of
7-propionate 2a (0.83 g, 3.0 mmol) in 2-butanone
(40 ml) and DMF (4 ml). The reaction mixture was heated to
60°C for 1 h before ZnCl2 (3.9 ml of 1.0 M solution in ether,
3.9 mmol) was added. The temperature was then raised to
70°C and the mixture stirred for 21 h at 70°C. The reaction
mixture was cooled to room temperature and quenched with
saturated aqueous NH4Cl (100 ml). The mixture was extracted with EtOAc (2×100 ml) and the combined organic layers
were washed with brine (100 ml) and dried over Na2SO4.
Evaporation of the solvent gave 1.9 g of crude product. After
column chromatographic purification, 280 mg (27% yield) of
9 was obtained as a waxy solid. Analysis of 9 gave the following results: melting point 85–88°C; 1H NMR (DMSO-d6)
δ 1.00 (3H, t, J = 7.2 Hz), 1.16 (3H, t, J = 7.5 Hz); 1.47
(6H, s), 1.61 (2H, m), 2.71 (2H, q, J = 7.5 Hz), 2.89 (2H, t,
J = 7.8), 5.84 (1H, d, J = 9.9 Hz), 6.17 (1H, s), 6.41 (1H, d,
J = 10.2 Hz), 6.81 (1H, s); 13C NMR (DMSO-d6) δ 8.6,
13.7, 22.8, 26.6, 27.2, 37.4, 78.3, 103.6, 107.2, 110.8, 113.4,
115.5, 130.1, 148.5, 151.4, 154.4, 156.9, 159.3, 172.2; IR
(film) 2972, 1767, 1723, 1616 cm-1; MS m/e 343 (M+1);
analysis calculated for C20H22O5: C, 70.16; H, 6.47. Found:
C, 70.37; H, 6.51.
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6,6-Dimethyl-9-pivaloyloxy-4-propyl-2H,6Hbenzo[1,2-b:3,4-b′]dipyran-2-one (10). A suspension of

2b (304 mg, 1 mmol) was prepared in 2-butanone (13 ml)
and DMF (1.3 ml). K2CO3 (346 mg, 2.5 mmol), 3-chloro3-methyl-1-butyne (0.56 ml, 5 mmol) and (n-Bu)4NI
(360 mg, 1 mmol) were then added to the suspension. The
reaction mixture was heated to 60°C for 1 h and then anhydrous ZnCl2 (1.0 M solution in ether, 1.3 ml) was added.
The reaction mixture was heated to 70°C for 26 h, then
cooled to room temperature, quenched with saturated
aqueous NH4Cl (25 ml) and extracted with ethyl acetate
(2×75 ml). The organic solutions were combined, washed
with brine, dried over Na2SO4 and concentrated. The concentrated crude product was purified by silica gel chromatography (8:1 hexane/ethyl acetate) to yield 10 as a yellow solid (270 mg, 73% yield) with the following analytical
profile: melting point: 65–68°C; Rf=0.54 (4:1 hexane/ethyl
acetate); 1H NMR (CDCl3) δ 1.04 (3H, d, J = 7.2 Hz),
1.39 (9H, s), 1.52 (6H, s), 1.66-1.71 (2H, m), 2.90 (2H, t,
J = 7.8 Hz), 5.62 (1H, d, J = 10.2 Hz), 6.07 (1H, s), 6.30
(1H, d, J = 10.2 Hz), 6.62 (1H, s); 13C NMR (CDCl3) δ
13.8, 22.9, 26.9, 27.8, 38.3, 39.3, 78.1, 103.5, 107.9, 110.9,
113.4, 115.9, 129.1, 148.9, 152.0, 155.1, 157.4, 160.6,
176.2; IR (film) 2967, 1750, 1616, 1364, 1142 cm-1; MS
m/e 371 (M+1); analysis calculated for C22H26O5: C, 71.33;
H, 7.07. Found: C, 71.08; H, 7.35.
6,6-Dimethyl-4-propyl-9-tosyloxy-2H,6H-benzo[1,2b:3,4-b′]dipyran-2-one (11). To a 100 ml, three-necked

round-bottomed flask equipped with a mechanical stirrer,
a condenser, a thermometer and N2 inlet/outlet were added
0.5 g (1.34 mmol) of 8, 20 ml of 2-butanone, and 2 ml
of DMF. This was followed by the addition of 0.46 g
(3.34 mmol) of K2CO3, 0.49 g (1.33 mmol) of (n-Bu)4NI.
To this reaction mixture, 0.44 ml (4.0 mmol) of 3-chloro3-methyl-1-butyne was added by syringe. The resulting
solution was heated to 60°C for 1 h, and then 1.74 ml of
1 M solution of ZnCl2 in ether was added. The reaction
mixture was stirred for 40 h at 70°C. After cooling to room
temperature, the mixture was diluted with EtOAc (100 ml)
and quenched with saturated aqueous NH4Cl. The aqueous
layer was extracted with EtOAc (2×50 ml). The combined
organic solution was washed with brine, dried over Na2SO4
and filtered. The solvent was removed under vacuum to
provide 0.8 g of crude product as a yellowish solid. The
crude product was then purified by column chromatography and the solid obtained was crystallized from EtOAc to
afford 0.3 g (50% yield) of the desired product 11 as a
white solid: melting point 150–151°C (148°C, Fox et al.,
2000); 1H NMR (DMSO-d6) δ 0.97 (3H, t, J = 7.1 Hz),
1.34 (6H, s), 1.57 (2H, m), 2.42 (3H, s), 2.84 (2H, t,
J = 7.6 Hz), 5.67 (1H, d, J = 10.2 Hz), 6.20 (1H, d, J = 8.4 Hz),
6.21 (1H, s), 6.68 (1H, s), 7.47 (2H, d, J = 7.5 Hz), 7.79
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(2H, d, J = 7.5 Hz); 13C NMR (DMSO-d6) δ 13.6, 21.1,
22.7, 27.0, 37.3, 78.5, 103.4, 108.4, 111.5, 114.1, 114.8,
128.6, 130.3, 130.6, 130.9, 146.1, 146.6, 151.6, 154.2,
156.6, 159.0. Analysis calculated for C24H24O6S: C, 65.44;
H, 5.49. Found: C, 65.32; H, 5.50.
6,6-dimethyl-9-hydroxy-4-propyl-2H,6H-benzo[1,2b:3,4-b′]dipyran-2-one (13). To a solution of ester 9

(223 mg, 0.65 mmol) in 15 ml of MeOH were added saturated aqueous solution of NaHCO3 (7 ml) and water
(7 ml). The reaction mixture was stirred at room temperature under N2 for 7 h until TLC indicated complete consumption of the starting material. The reaction mixture was
then acidified with 10% aqueous HCl (100 ml) and
extracted with EtOAc (50 ml). The organic solution was
washed with brine (100 ml) and dried over Na2SO4.
Evaporation of the solvent yielded the crude product that
was purified by preparative TLC to afford 97 mg (52%
yield) of 13 as a solid. Analysis of that product yielded the
following analytical data: melting point 190–192°C
(190°C, Fox et al., 2000); 1H NMR (DMSO-d6) δ 0.99
(3H, t, J =7.3Hz), 1.45 (6H, s), 1.59 (2H, sextet, J =7.5Hz),
2.83 (2H, t, J =7.6Hz), 5.66 (1H, d, J=9.9Hz), 5.92 (1H, s),
6.34 (1H, s), 6.57 (1H, d, J =9.9Hz), 10.77 (1H, s); 13C
NMR (DMSO-d6) δ 13.7, 22.9, 27.2, 37.5, 77.5, 95.7,
102.2, 106.1, 109.9, 116.3, 127.1, 151.7, 155.7, 156.4,
157.8, 160.0; IR (film) 3185, 1686, 1582, 1381, 1157 cm-1;
MS m/e 287 (M+1); analysis calculated for C17H18O4: C,
71.31; H, 6.34. Found: C, 71.39; H, 6.40.
Preparation of 13 from tosylate 11. Compound 13 can
be also obtained from detosylation of 11. To a 100 ml,
three-necked round-bottomed flask equipped with a stir
bar and N2 inlet/outlet was added 1.8 g (4.09 mmol) of 11
and 40 ml of THF. The solution was cooled to 0°C, and
6.2 ml (6.2 mmol) of a 1.0 M solution of (n-Bu)4NF in
THF was added by the syringe. The resulting mixture was
stirred at 0°C for 7 h. The solvent was then removed under
vacuum to furnish a green-brown oil which was diluted
with EtOAc (500 ml) and washed with water (300 ml).
The aqueous layer was extracted with EtOAc (2×100 ml).
The organic layers were combined, washed with brine
(100 ml), dried over Na2SO4 and filtered. The solvent was
removed under vacuum to provide 2.1 g of crude product as
a green-brown oil. The oil was further purified by column
chromatography followed by crystallization from EtOAc to
afford 0.5 g (43% yield) of 13 as a white solid, which was
identical to the compound obtained from 9.
6,6-dimethyl-9-(2-methyl-2-methoxycarbonylpropyloxy)-4-propyl-2H,6H-benzo[1,2-b:3,4-b′]dipyran-2one (15). To compound 13 (430 mg, 1.50 mmol), Ph3P

(590 mg, 2.25 mmol) and methyl 2,2-dimethyl-3-hydroxy
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propionate (396 mg, 3 mmol) in dioxane (34 ml) was added
DEAD (360 µl, 2.25 mmol) and stirred at reflux under N2
for 2 h. The reaction mixture was cooled to room temperature and concentrated under vacuum. The residue was dissolved in ethyl acetate (100 ml) and washed with water
(80 ml), dried (Na2SO4), concentrated under vacuum and
purified by silica gel chromatography (3/1 hexane/ethyl
acetate) to afford 15 (445 mg, 74% yield) as a white solid.
The analytical data were as follows: melting point:
100–101°C; 1H NMR (CDCl3) δ 1.03 (3H, t, J = 7.4 Hz),
1.35 (6H, s), 1.49 (6H, s), 1.65 (2H, sextet, J = 7.5 Hz),
2.89 (2H, t, J = 7.8 Hz), 3.71 (3H, s), 4.00 (2H, s), 5.52
(1H, d, J = 9.9 Hz), 5.96 (1H, s), 6.37 (1H, s), 6.56 (1H, d,
J = 10.2 Hz); 13C NMR (CDCl3) δ 13.8, 22.3, 23.0, 27.7,
38.3, 43.2, 52.1, 74.8, 77.7, 93.3, 104.3, 107.2, 111.2,
116.3, 127.1, 151.7, 156.4, 156.7, 158.1, 161.3, 176.2; IR
(film) 2878, 1726, 1605, 1364, 1155 cm-1; MS m/e 401
[M+1]; analysis calculated for C23H28O6: C, 68.98; H, 7.05.
Found C, 69.16; H, 7.12.
6,6-dimethyl-9-(2-methyl-2-carboxylpropyloxy)-4propyl-2H,6H-benzo[1,2-b:3,4-b′]dipyran-2-one (16).

To a solution of compound 15 (40 mg, 0.1 mmol) in
methanol (2 ml) was added KOH (25 mg, 0.45 mmol) in
water (1 ml). The resulting solution was stirred at room
temperature for 3 h, whereupon it was concentrated under
vacuum. Water was then added to the residue which was
acidified with 1N HCl and extracted with ethyl acetate.
The organic extracts were combined and washed with
brine, dried (Na2SO4) and concentrated under vacuum to
furnish 16 (30 mg, 78% yield) as a white solid. Analysis of
the product revealed the following characteristics: melting
point: 140–142°C; 1H NMR (CDCl3) δ 0.99 (3H, t, J = 7.6
Hz), 1.38 (6H, s), 1.48 (6H, s), 1.65 (2H, sextet, J = 7.4
Hz), 2.89 (2H, t, J = 7.7 Hz), 4.02 (2H, s), 5.51 (1H, d,
J = 9.9 Hz), 5.98 (1H, s), 6.38 (1H, s), 6.59 (1H, d,
J = 10.2 Hz); 13C NMR (CDCl3) δ 13.8, 22.1, 23.0, 27.7,
38.3, 43.1, 74.4, 77.7, 93.3, 104.3, 107.3, 111.2, 116.4,
127.1, 151.8, 156.4, 156.6, 158.2, 161.4, 181.4; IR (film)
3381–3073, 2963–2750, 1740, 1605, 1474, 1385,
1163 cm-1; MS m/e 387 [M+1]; analysis calculated for
C22H26O6·0.2H2O: C, 67.75; H, 6.92. Found C, 67.75; H,
6.81.
7,8-cis-10,11,12-trans-4-propyl-6,6,10,11-tetramethyl7,8,9-trihydroxy-2H,6H,12H-benzo[1,2-b:3,4-b′:5,6b′′]tripyran-2-one (18). To a round-bottom flask

equipped with magnetic stirrer were added acetone (10 ml)
(±)-calanolide A (17) (Flavin et al., 1996) (0.5 g,
1.35 mmol), t-butylammonium acetate (88.4 mg,
0.34 mmol), and t-butylhydroperoxide (70%, 0.3 ml,
2.19 mmol). The solution was stirred at room
temperature until a homogeneous solution was obtained.
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The temperature of the solution was then lowered to 0°C.
A solution of OsO4 (1 mg, 0.004 mmol) in t-butyl alcohol
was added. The reaction mixture turned purple. After stirring for 1 h, the cold bath was removed and the reaction
mixture was warmed up to room temperature and stirred
for 30 h. Ether (10 ml) was added and the resulting mixture cooled to 0°C, followed by addition of freshly prepared
10% aqueous NaHSO3 (15 ml). The cold bath was removed
and stirring was continued for another hour to afford a
two-layer solution. Solid NaCl was added to the aqueous
layer until it was saturated. The two-phase solution was
stirred for 10 mins; the organic layer was then separated
and the aqueous phase extracted with ether (3×10 ml). The
combined organic phase was washed with brine, dried
(Na2SO4) and concentrated to yield a brown residue as the
crude product. The crude product was purified by 2mmChromatotron with ethyl acetate/hexane (1:4) as the eluent
to afford compund 18 (130 mg, 24% yield), a mixture of
two isomers at a ratio of approximately 2.5:1. The analytical data were as follows: 1H NMR (400 MHz, CDCl3) δ
[with minor isomer listed in brackets] 1.02 (3H, t,
J = 7.4 Hz), 1.16 (3H, d, J = 6.8 Hz), 1.37 (3H, s), 1.50
(3H, d, J = 6.4 Hz), 1.52 (3H, s), 1.63 (2H, sextet,
J = 7.2 Hz), 1.98 (1H, m), 2.80–2.95 (2H, m), 3.21 (1H,
m), 3.59 (1H, broad-s), 3.82 (1H, m), 4.12 (1H, dq, J = 6.6,
8.4 Hz), 4.76 (1H, d, J = 7.2 Hz) [4.73 (d, J = 7.2 Hz)],
5.02 (1H, d, J = 5.2 Hz) [4.99 (m)], 5.98 (1H, s); 13C NMR
(100.5 MHz, CDCl3) δ [with the minor isomer listed in
bracket] 13.9 [14.2], 15.2 [15.0], 19.3 [19.2], 22.6, 23.2,
24.0, 39.1 [38.9], 40.0 [40.5], 62.4 [62.1], 66.6 [66.9], 69.9
[70.2], 77.9 [78.0], 78.9 [79.1], 104.4, 106.1, 106.3, 110.8
[110.9], 151.1, 155.0, 156.0, 159.3, 160.3; IR (film) 3441,
2971–2874, 1711, 1595, 1379, 1113 cm-1; MS m/e 405
(M+1); analysis calculated for C22H28O7: C, 65.33; H, 6.98.
Found C, 65.54; H, 7.20.
7,8-trans-10,11,12-trans-8-(3-chlorobenzonyloxy)7,12-dihydroxy-4-propyl-6,6,10,11-tetramethyl2H,6H,12H-benzo[1,2-b:3,4-b′:5,6-b′′]tripyran-2-one
(19). To a solution of (±)-calanolide A (17) (0.4 g,

1.1 mmol) in CH2Cl2 (2 ml) at 0°C was added a solution
of m-chloroperbenzoic acid (MCPBA) (0.5 g, 2.9 mmol).
The reaction mixture was stirred at 0°C for 3 h. The
reaction was quenched with 10% aqueous sodium sulfite
solution (15 ml), followed by saturated NaHCO3 solution
(5 ml). The resulting two layers were separated and the
aqueous layer was extracted with CH2Cl2 (3×5 ml). The
combined organic phase was washed with brine and dried
over Na2SO4. Concentration under reduced pressure
yielded a yellow residue that was purified by 2-mm chromatotron with ethyl acetate/hexane (1:3) as the eluent to
afford benzoate 19 (178.6 mg, 46% yield) which was a
mixture of isomers at a ratio of 3:1. The compound had the
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following physical and chemical data: 1H NMR (CDCl3)
δ [with the minor isomer listed in bracket] 1.04 (3H, d, J =
6.4 Hz), 1.05 (3H, t, J = 7.2 Hz), 1.13 (3H, d,
J = 7.16.4 Hz), [1.18 (d, J = 6.4 Hz)], 1.11 (3H, d,
J = 6.3 Hz), 1.26 (3H, s), 1.46 (3H, s), 1.56 (3H, s), 1.67
(2H, sextet, J = 7.6 Hz), 1.90 (1H, m), 2.91 (2H, mt,
J = 7.8 Hz), 3.83 (1H, dq, J = 6.4, 9.0 Hz) [4.08 (m)],
4.69 (1H, d, J = 7.8 Hz), 5.98 (1H, s), 6.18 (1H, d,
J = 4.2 Hz) [6.41 (d, J = 5.1 Hz)], 7.34 (1H, t, J = 8.0 Hz),
7.66 (1H, dd, J = 2.1, 7.8 Hz), 7.86 (1H, dd, J = 2.2, 7.8
Hz), 7.96 (1H, t, J = 1.8 Hz); 13C NMR (CDCl3) δ [with
minor isomer listed in brackets] 13.8 [14.0], 14.7 [14.8],
18.5, 23.2 [21.8], 24.1 [22.6], 29.3 [29.5], 31.8, 38.9, 40.4
[40.3], 67.0 [66.8], 69.2, 72.6 [71.6], 77.2, 79.2, 103.2,
104.0, 107.0, 110.6, 127.9, 129.9, 131.6, 133.4, 134.8,
152.0, 155.9, 157.1, 159.3, 160.5, 165.8; IR (film)
3434, 2965–2872, 1728, 1710, 1597, 1252, 1117 cm–1;
MS m/e 545 and 543 (M+), 527 and 525 (M-H2O), 387
(M-C7ClH4O2), 369 (M-H2O-C7ClH4O2); analysis
calculated for C29ClH31O8: C, 64.15; H, 5.75. Found C,
63.82; H, 5.95.
3,4-trans-6,7,8-trans-10-(2-methoxycarbonyl-1-propylethenyl)-3,4,8,9-tetrahydroxy-2,2,6,7-tetramethyl2H,8H-benzo[1,2-b:3,4-b′]dipyrane (20) and 7,8-trans10,11,12-trans-4-propyl-6,6,10,11-tetramethyl-7,8,12trihydroxy-2H,6H,12H-benzo[1,2-b:3,4-b′:5,6b′′]tripyran-2-one (21). To a solution of benzoate 19

(1.2 g, 2.2 mmol) was added a solution of NaOMe in
MeOH (15 ml), freshly prepared by addition of a small
piece of sodium to MeOH. The solution was stirred at
room temperature for 3 days. The solvent was then
removed under reduced pressure to yield a yellow solid,
which was further purified by chromatography with ethyl
acetate/hexane (25% to 40% gradient) as the eluent.
Compound 20 (275.7 mg, 29% yield) was collected first
followed by 21 (69.8 mg, 8% yield). Compound 20, a mixture of isomers with a ratio of approximately 2.5:1. The
analytical data were as follows: 1H NMR (400 MHz,
CDCl3) δ [with the minor isomer listed in brackets] 1.02
(3H, t, J = 7.6 Hz), 1.16 (3H, d, J = 6.8 Hz), 1.45 (6H, s),
1.48 (3H, d, J = 6.4 Hz), 1.63 (2H, sextet, J = 7.5 Hz),
1.87–1.95 (1H, m), 2.85–2.95 (2H, m), 2.90 (1H, d,
J = 8.0 Hz), 3.57 (1H, d, J = 3.4 Hz) [3.54 (d, J = 3.4 Hz)],
3.63 (3H, s) [3.66 (s)], 3.80 (1H, dd, J = 5.0, 8.5 Hz) [3.78
(dd, J = 5.1, 8.5 Hz)], 4.05 (1H, dq, J = 6.8, 8.1 Hz) [3.89
(dq, J = 6.8, 10.0 Hz)], 4.51 (1H, d, J = 4.8 Hz) [4.46 (d,
J = 5.4 Hz)], 4.76 (1H, dd, J = 5.0, 8.6 Hz) [4.73 (dd, J =
3.8, 7.4 Hz)], 5.93 (1H, s); 13C NMR (100.5 MHz,
CDCl3) δ [with minor isomer listed in brackets] 13.9, 15.1
[14.9], 18.9, 21.5 [20.6], 23.2 [23.3], 26.1 [26.5], 39.0
[39.1], 40.3 [40.6], 60.0 [60.6], 67.1 [67.3], 70.7 [71.1],
71.2, 77.2 [77.5], 79.1 [79.0], 104.0 [103.8], 105.8, 106.4

Antiviral Chemistry & Chemotherapy 13:1

[106.5], 110.2, 151.6 [151.5], 155.4 [155.5], 156.9
[157.3], 159.4, 160.5; MS m/e 436 (M+), 419 (M-H2O),
401 (M-2 H2O), 369 (M-H2O-MeO).
The analytical data for compound 21 were as follows:
1
H NMR (400 MHz, CDCl3) δ 1.02 (3H, t, J = 7.4 Hz),
1.15 (3H, d, J = 6.8 Hz), 1.37 (3H, s), 1.50 (3H, d, J = 6.4
Hz), 1.51 (3H, s), 1.63 (2H, sextet, J = 7.5 Hz), 1.99 (1H,
sextet, J = 7.5 Hz), 2.81–2.95 (2H, m), 3.22 (1H, d, J = 4.4
Hz), 3.65 (1H, broad-s), 3.81 (1H, t, J = 4.6 Hz), 3.93 (1H,
d, J = 1.6 Hz), 4.12 (1H, dq, J = 6.6, 8.4 Hz), 4.76 (1H, dd,
J = 2.4, 7.2 Hz), 5.03 (1H, dd, J = 1.8, 5.0 Hz), 5.98 (1H,
s); 13C NMR (100.5 MHz, CDCl3) δ 13.9, 15.2, 19.2, 22.6,
23.2, 24.1, 39.1, 40.0, 62.4, 66.5, 70.0, 77.9, 78.9, 104.4,
106.2, 106.3, 110.7, 151.0, 155.0, 156.0, 159.4, 160.4; MS
m/e 405 (M+1), 387 (M-OH), 369 (M-OH-H2O).
7,8-trans-10,11-trans-8-(3-chlorobenzonyloxy)-7hydroxy-4-propyl-6,6,10,11-tetramethyl-2H,6H,12Hbenzo[1,2-b:3,4-b′:5,6-b′′]tripyran-2,12-dione (23). To

a solution of trans-(±)-ketone 22 (Flavin et al., 1996)
(0.40 g, 1.1 mmol) in CH2Cl2 (2 ml) at 0°C was added a
solution of MCPBA. The reaction mixture was stirred at
0°C for 3 h. The reaction was quenched with 10% aqueous
sodium sulfite solution (15 ml), followed by saturated
NaHCO3 solution (5 ml). The resulting two layers were
separated and the aqueous layer was extracted with CH2Cl2
(3×5 ml). The combined organic phase was washed with
brine and dried over Na2SO4. Concentration under reduced
pressure yielded a yellow residue which was purified by 2mm chromatotron with ethyl acetate/hexane (1:3) as the
eluent to furnish benzoate 23 as a white solid (353 mg, 59%
yield), which is a mixture of isomers with a ratio of 2:1. The
analytical profile was: 1H NMR (CDCl3) δ [with the minor
isomer listed in brackets] 1.04 (3H, t, J = 7.4 Hz), 1.14
(3H, dd, J = 1.4, 7.1 Hz), 1.22 (3H, d, J = 6.3 Hz), 1.54
(3H, s), 1.59 (3H, s), 1.60–1.80 (2H, m), 2.31 (1H, d, J =
2.4 Hz), 2.40-2.55 (1H, m), 2.80–3.00 (2H, m), 4.01 (1H,
dd, J = 2.3, 4.4 Hz), 4.20–4.30 (1H, m), 6.08 (1H, s), 6.23
(1H, d, J = 4.2 Hz) [6.48 (1H, d, J = 5.1 Hz)], 7.41 (1H, t,
J = 8.0 Hz), 7.59 (1H, dd, J = 1.2, 8.1Hz), 7.90 (1H, dd,
J = 2.2, 7.8 Hz), 7.98 (1H, t, J = 2.2 Hz); MS m/e 542
(M+1).
7,8-cis-10,11-trans-7,8-dihydroxy-4-propyl-6,6,10,11tetramethyl-2H,6H,12H-benzo[1,2-b:3,4-b′:5,6b′′]tripyran-2,12-dione (24). To a vigorously stirred solu-

tion of trans-(±)-ketone 22 (1.0 g, 2.7 mmol) in ethyl
acetate/acetonitrile (1:1, 16 ml) at 0°C was added a solution of RuO2 (42.7 mg, 0.2 mmol) and NaIO4 (1.8667 g,
14.0 mmol) in distilled water. The resulting solution turned
brown after it had been stirred vigorously at 0 oC for 3.5 h.
Saturated Na2SO3 solution (25 ml) was then added. The
layers were separated and the aqueous phase was extracted
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with ethyl acetate (5×15 ml). The combined organic phase
was dried over Na2SO4 and concentrated to yield a black
residue which was then dissolved in ethyl acetate (10 ml)
and passed through a short silica gel column (5 cm) with
ethyl acetate as the eluent. The collected solution was concentrated to afford a brown solid which was further purified via 2-mm Chromatotron with ethyl acetate/hexane
(1:2) as the eluent to provide 24 (91 mg, 8% yield), a mixture of two isomers at a ratio of approximately 1.2:1 with
these characteristics: 1H NMR (400 MHz, CDCl3) δ [with
the minor isomer listed in brackets] 1.01 (3H, t, J = 7.2
Hz), 1.24 (3H, d, J = 7.2 Hz) [1.23 (d, J = 6.0 Hz)], 1.44
(3H, s) [1.46 (s)], 1.55 (3H, s) [1.53 (s)], 1.58 (3H, d,
J = 6.8 Hz) [1.60 (d, J = 6.4 Hz)], 1.61 (2H, m), 2.60 (1H,
m), 2.86 (2H, m), 3.22 (1H, t, J = 5.2 Hz), 3.67 (1H, d, J =
2.8 Hz) [3.53 (d, J = 2.8 Hz)], 3.85 (1H, m), 4.47 (1H, dq,
J = 6.3, 10.0 Hz) [4.37 (dq, J = 6.4, 9.9 Hz)], 5.05 (1H, s),
6.05 (1H, s); 13C NMR (CDCl3) δ [with the minor isomer
listed in brackets] 10.1 [10.5], 13.7 [14.0], 19.7 [19.6], 22.0
[21.6], 23.0 [22.5], 24.6 [24.9], 31.5, 39.0, 47.0 [47.1],
53.4, 61.7, 70.0 [70.2], 80.3 [80.4], 103.6, 104.7, 106.3,
106.6, 112.4, 156.0 [155.8], 157.8, 162.9 [163.2], 189.5; IR
(film) 3461, 2972–2874, 1732, 1717, 1701, 1609, 1583,
1559, 1208, 1115 cm–1; MS m/e 403 (M+1), 385 (M-OH);
analysis calculated for C22H26O7: C, 65.66; H, 6.51. Found
C, 65.50; H, 6.56.
9-hydroxy-4-propyl-6,6-dimethyl-10-(1-oxo-2,3-dihydroxy-2-methyl-butyl)-2H,6H-benzo[1,2-b:3,4b2]dipyran-2-one (25). To a solution of trans-(±)-ketone

22 (0.50 g, 1.3 mmol) in CH2Cl2 (5 ml) and MeOH
(15 ml) was added H2O2 (0.25 ml, 50% aqueous solution,
0.30 g, 4.1 mmol) at 15°C, followed by a dropwise addition
of NaOH solution (2.5 ml, 0.275 M aqueous solution,
0.68 mmol). After the yellow solution was stirred at 15°C
for 24 h, water (20 ml) and ether (15 ml) were added. The
two layers were separated and the aqueous layer was further
extracted with ether (3×15 ml). The unreacted starting
ketone 22 (320 mg, 64%) was recovered from the combined
ethereal solution. The aqueous phase was then acidified
with concentrated HCl solution until the pH 3 and extracted again with ether (3×10 ml) extractions. The combined
ethereal solution was concentrated to afford compound 25
(67 mg, 13% yield) as an orange solid with the following
profile: 1H NMR (CDCl3) δ 1.03 (3H, t, J = 7.2 Hz), 1.23
(3H, d, J = 6.0 Hz), 1.32 (3H, d, J = 7.2 Hz), 1.44 (3H, s),
1.46 (3H, s), 1.66 (2H, sextet, J = 7.5 Hz), 2.91 (2H, m),
4.89 (1H, dq, J = 7.5, 7.8 Hz), 5.61 (1H, d, J = 9.9 Hz),
6.04 (1H, s), 6.62 (1H, d, J = 10.2 Hz); 13C NMR (CDCl3)
δ 13.1, 13.8, 16.2, 23.0, 27.2, 27.3, 38.4, 45.5, 76.7, 78.8,
106.6, 111.6, 112.6, 117.6, 129.1, 131.7, 142.3, 143.2,
143.5, 159.6, 161.7, 179.3; IR (film) 3192–2872, 1717,
1593, 1458, 1136 cm–1; MS m/e 403 (M+1); analysis
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calculated for C22H26O7·1.5H2O: C, 61.53; H, 6.80. Found
C, 60.97; H, 6.51.

Evaluation of coagulation inhibitory activity
Compounds 7, 9 and 18 were evaluated for anticoagulant
activity in prothrombin timing and partial thromboplastin
timing (aPTT) assays. Two dilutions of each compound
were added to human plasma from normal individuals with
no known coagulopathies to a final concentration of
10 µg/ml or 1 µg/ml. DMSO, the compound solvent, was
also evaluated using the same concentrations of DMSO
found in the two compound dilutions. The assays were
done with a Dade Behring Sysmex CA 500 coagulation
analyser (Dade Behring, Chicago, Ill., USA) using the protocol and reagents specified for that instrument.

Materials and methods: virology
Solubilization of Compounds
The coumarin analogues were dissolved in DMSO prior to
dilution in culture medium for antiviral assays. Ribavirin
was soluble in aqueous media.

Cells and virus
African green monkey kidney cells (CV-1 cells) were
obtained from American Type Culture Collection (ATCC,
Manassas, Va., USA). The cells were grown in minimal
essential medium (MEM, Gibco-BRL, Gaithersburg,
Md., USA) supplemented with 0.1% NaHCO3 and 10%
fetal bovine serum (FBS, Hyclone Laboratories, Logan,
UT, USA). When performing antiviral assays, serum was
reduced to 2%, and 50 µg/ml gentamicin (Sigma Chemical
Company, St. Louis, Mo., USA) was added to the medium.
Measles virus strain CC was obtained from
Pennsylvania State University (Beavertown, Pa., USA) and
the Edmonston wild-type strain purchased from ATCC.
Strains MO2 and MO6 were kindly provided by P Wyde
(Baylor College of Medicine, College Station, Tex., USA).
All other strains were acquired from PA Rota and JS Rota
(Centers for Disease Control and Prevention, Atlanta, Ga.,
USA).
For all studies, except for the multiplicity of infection
(MOI) study, the viral MOI used ranged from
0.0005–0.001 for each virus tested.

Cytopathic effect inhibition assay
The protocol of Barnard et al. (1997a) was used.
Compounds were tested at varying concentrations (seven
0.5 log10 dilutions) one time with this assay and the activity was then verified spectrophotometrically by neutral red
(NR) uptake assay on the same plate (see below). Virus and
compound were added in equal volumes to near-confluent
cell monolayers in 96-well tissue culture plates. The MOI
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used was virus-dependent and selected for each strain such
that 100% of the cells in the virus controls showed cytopathic effects (CPE) within 5–10 days for most MV
strains. The plates were incubated at 37°C until the cells in
the virus control wells showed complete viral CPE as
observed by light microscopy. Each concentration of drug
was assayed for virus inhibition of viral CPE in quadruplicate and for cytotoxicity in duplicate. Four wells were set
aside as uninfected, untreated cell controls per test and four
wells per test compound received virus in medium only and
represented controls for virus replication. Ribavirin was
included as a positive control drug for each set of compounds tested. For all CPE-based assays, the 50% effective
concentrations (EC50) were calculated by linear regression
analysis of the means of the CPE ratings expressed as percentages of untreated, uninfected controls for each concentration.
Morphological changes resulting from cytotoxicity of a
compound were graded on a scale of 0–5; 5 being defined
as complete cytotoxicity. The 50% cytotoxic doses (IC50)
were calculated by regression analysis and a selectivity index
(SI) was calculated using the formula: SI = IC50/EC50.

Neutral red uptake assay of CPE inhibition and
compound cytotoxicity
This assay was done on the same CPE inhibition test plates
described above to verify the inhibitory activity and the
cytotoxicity observed by visual observation. The usual correlation between visual and NR assays in our hands has
been greater than 95% (Barnard, 1997a). The NR assay was
performed using a modified method of Cavenaugh et al.
(1990) as described by Barnard et al. (1999). Briefly, medium was removed from each well of a plate, 0.034% NR
added to each well of the plate and the plate incubated for
2 h at 37°C in the dark. The NR solution was removed
from the wells, rinsed and the remaining dye extracted
using ethanol buffered with Sörenson’s citrate buffer.
Absorbances at 540/450 nm were read with a microplate
reader (Bio-Tek EL 1309; Bio-Tek Instruments, Inc.,
Winooski, Vt., USA). Absorbance values were expressed as
percents of untreated controls and EC50, IC50 and SI values
were calculated as described above.

previously by Barnard et al. (1997b).
A 90% reduction in virus yield was then calculated by
linear regression analysis. This represented a 1 log10 inhibition in titre when compared to untreated virus controls.

Virucidal assay
For compounds showing good antiviral inhibitory activity,
a virucidal test was done to exclude the possibility that the
compounds inhibited the virus by physically inactivating
or disrupting the virion. The method of Barnard et al.
(1997b) was used. Equal volumes of undiluted virus stock
and a single concentration of compound were incubated at
37°C for 1 h. Surviving virus was quantified by CPE assay
and titres were calculated as described previously by
Barnard et al. (1997b). Concentrations of compound tested bracketed the concentration determined to represent
the EC50; each concentration of test compound was
assayed in quadruplicate.

Evaluation of cytotoxicity in rapidly
dividing cells
Cytotoxicity in rapidly dividing cells was evaluated by
determining the total number of cells as reflected by a NR
uptake assay after a 3-day exposure to several concentrations of compound. The method of Barnard et al. (1997b)
was used. To quantitate cell growth after 72 h in the presence or absence of drug, the plates were then treated as
described above for the NR assay. Absorbance values were
expressed as percent of untreated controls and IC50 values
were calculated by regression analysis.

Determining the influence of multiplicity of
infection
This assay was done as described previously by Barnard
et al. (1997a). Virus (strain Chicago) was used for the study
of the inhibition by selected compounds at different MOIs
ranging from 0.0004–0.04 µg/ml (see Table 5).
Compounds at varying concentrations were evaluated as
described above for the CPE inhibition and NR assays in
the presence of virus at a selected MOI. EC50 and IC50 values were determined as previously described.

Evaluation of the timing of treatment initiation
Virus Yield Reduction Assay
All compounds with a SI greater than 10 were evaluated in
a more sensitive assay to confirm the results of the CPE
inhibition/NR uptake assays. Infectious virus yields from
each well from a second CPE inhibition assay were determined as previously described (Barnard, et al., 1997b).
After CPE was scored as described above, each plate was
frozen at –80°C and thawed. Sample wells at each compound concentration tested were pooled and titered in
CV-1 cells for infectious virus by CPE assay as described
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The time that the compound was added to the plates was
varied relative to the time of virus exposure. Varying dilutions of test compounds were added to the cells without
removal of the virus (MOI = 0.04) at 1, 2, 4, 8 and 24 h
post virus exposure. When a treatment was done 1 h before
virus was added, compound was added to the wells and
incubated at 37°C for 1 h, after which virus was added to
each well in a small volume. At ‘0’ time, the virus was added
within 5 min of drug addition as described previously for
the CPE inhibition assay (Barnard et al., 1997a). The EC50,
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IC50 and SI values were derived from visual and NR assays
as described above. The Chicago strain of MV was used for
this study.

Evaluation of drug combinations
Concentrations of test compound (0.0032–10 µg/ml) were
evaluated alone and in combination with varying concentrations of ribavirin (0.032–32 µg/ml) against the Chicago
strain of MV. All combinations, as well as each drug concentration used alone, were done in quadruplicate in 96well microplates. Toxicity controls for each combination
were also run in parallel on the same plate; these consisted
of uninfected cells similarly treated with each drug combination as well as each concentration of either drug used
alone. Ribavirin was tested from 0.32–320 µg/ml and 7
from 0.01–32 µg/ml. Visual and NR assays were used to
generate EC50 or an IC50 values for each compound used
alone or in combination.
The evaluation of synergism was done utilizing the 3dimensional computerized system of Prichard & Shipman
(1990) with the MacSynergy™ computer program.

Results: chemistry
It has been reported (Flavin et al., 1996) that 5,7-dihydroxy-4-propylcoumarin (1) was selectively acylated under
the modified Friedel-Crafts reaction conditions to form
5-hydroxy-7-propionyloxy-4-propylcoumarin (2a) in a
10% isolated yield. Due to the low yield from that synthesis, a more practical procedure needed to be developed.
Thus, a variety of reaction conditions were investigated
and are summarized in Table 1. Without a Lewis acid such
as AlCl3 or bases such as pyridine and 4-dimethylaminopyridine (DMAP), no reaction took place between
coumarin 1 and propionyl anhydride (entries 1 and 2 in
Table 1). The reported conditions using AlCl3 (Flavin et
al., 1996) were repeated and led to 20% conversion to 2a,
as indicated by HPLC analysis (entry 3). The best results
were obtained when a catalytic amount of pyridine was
used (entry 4), resulting in a 47% conversion to 2a along

with a small amount of the corresponding diester 3a
(Scheme 1) and some unreacted starting material 1. The
formation of the diester 3a could be minimized by shortening the reaction time or lowering the reaction temperature, which, however, also decreased the yield of the
monoester 2a with increased recovery of the unreacted
starting 1 (entry 5). On the other hand, prolonged reaction
time or increasing the reaction temperature increased the
conversion of the starting material 1 to 2a, which was
accompanied by an increase in the formation of undesired
3a and led to more difficulty in purification of 2a. It
appeared that DMAP might have been too strong a base
(entries 6 and 7) and proprionyl chloride too reactive an
acylating agent (entry 8) for the selective acylation.
Therefore, the pyridine-promoted acylation was scaled up
in a 50 g scale reaction, affording a 36% isolated yield of
2a. As reported by Flavin et al. (1996), 2a was positive in
a Gibbs colour test, resulting in a greenish blue colour
characteristic of p-unsubstituted phenol ( Josephy &
Damme, 1984). Furthermore, a COSY/NOSY NMR
spectrum showed that the free hydroxyl group (5-OH) at
11.10 ppm only correlated with one aromatic proton (H6)
at 6.57 ppm, which was supported by NOE enhancements
(20%) observed between these two protons. The results
further confirmed the structural assignment, since the
hydroxyl group (7-OH) would be expected to correlate
with both aromatic protons (H6 and H8) should the propionyl group be attached to the 5-OH.
For the introduction of a more bulky group at the
7-position of 1, a more reactive acylating agent such as acyl
chloride was used. For example, the reaction between 1 and
pivaloyl chloride at room temperature for 4 days in the
presence of pyridine yielded 7-monosubstituted 2b and
5,7-disubstituted 3b in isolated yields of 36% and 18%,
respectively. The bispivaloate 3b was exclusively formed
when 1 was reacted with 2 equivalents of pivaloyl chloride.
It is worthwhile noting that reaction of 1 with 1.0 equivalent TBDMS-Cl in the presence of imidazole in DMF
afforded 31% of 7-TBDMS substituted 2c, along with 24%
of 5,7-bis(TBDMS) substituted 3c (Scheme 1). The

Table 1. Acylation of coumarin 1 with propionyl anhydride to form 7-monoester 2a
Entry
1
2
3
4
5
6
7
8

10

Reaction conditions
In THF at 0°C for 2 h
In THF at 30°C for 2 h
AlCl3 (2 equivalents) in 1,2-dicholorethane at room temperature for 24 h
Pyridine (3 drops) in THF at room temperature for 1.5 h
Pyridine (3 drops) in THF at room temperature for 1 h
4-dimethylaminopyridine (0.1 equivalents) in 1,2-dicholorethane at
room temperature for 4 h
4-dimethylaminopyridine (0.1 equivalents) in 1,2-dicholorethane at 0°C
for 45 min
Propionyl chloride in pyridine at 0°C for 4 h

HPLC Yield of 2a
No reaction
No reaction
20%
47%
26%
Complicated mixture
47% isolated yield of 3a
Complicated mixture
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Scheme 1.
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C-acylated coumarins 4, 5, and 6 were prepared using the
method of Flavin et al. (1996) and shown in Scheme 1.
The tosylated compounds 7 and 8 were prepared
according to the methods of Desai et al. (1956) and Fox et
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OH

O

7

O

TsO

O

O

8

al. (2000) with some modifications. Thus, tosylation of 1
with tosyl chloride and potassium carbonate led to
bistosylate 7 with a 90% yield. Treatment of 7 with
1.0 equivalent of TBAF under mild conditions afforded
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Scheme 3.
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the corresponding monotosylate 8 with a 43% yield
(Scheme 2).
Chromenylation of 2a was initially attempted employing 4,4-dimethyoxy-2-methylbutan-2-ol (Flavin et al.,
1996), but only approximately 5% of 9 was detected by 1H
NMR. However, when 3-chloro-3-methyl-1-butyne was
used in the presence of zinc chloride and phase transfer
catalyst tetrabutylammonium iodide (Chenera et al.,
1993; Bell et al., 1995), 9 was obtained in a 27% isolated
yield (Scheme 3). The same procedure on 2b afforded 10
in an impressive 73% yield. Similarly, compound 11 (Fox
et al., 2000) was successfully synthesized from 8 by using
3-chloro-3-methyl-1-butyne and zinc chloride with a
50% yield. In contrast, when 2c was reacted with

12

O

14

3-chloro-3-methyl-1-butyne under the same conditions,
a tripyranone derivative 12 (Games et al., 1971) was
formed without detection of the corresponding dipyranone. The structure assignment of 12 was based on 1H
NMR and MS. This indicated that the TBMDS-protecting group was lost during the course of chromenylation.
Compound 14 was prepared by reacting 5 with 4,4dimethyoxy-2-methylbutan-2-ol as described by Flavin et
al. (1996) (Scheme 3).
Compound 13 was obtained through hydrolysis of 9–11
under basic conditions. For example, conversion of 9 to
13 was uneventful with sodium bicarbonate in aqueous
MeOH and 13 was obtained in a 44% yield (Scheme 3).
Similarly, treatment of 11 with TBAF at 0°C afforded 13
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Scheme 4.
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Scheme 6.
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with a 43% yield. It is worthwhile to note that direct
chromenylation of 1 with 4,4-dimethyoxy-2-methylbutan2-ol resulted in a mixed product, with 13 being isolated in
less than a 10% yield (Bell et al., 1995).
Alkylation of 13 with commercially available methyl
2,2-dimethyl-3-hydroxy propionate under Mitsunobu conditions furnished 15 with a 69% yield, which was then

14

O

HO

HO

HO

O

O

O

25

hydrolyzed to acid 16 under basic conditions with a 78%
yield (Scheme 4).
The preparation of cis-isomer of 7,8-dihydroxy calanolide A (18) from (±)-canalolide A (17) was straightforward
using OsO4/tBuOOH. Separation of the diastereomeric
mixture by chromatographic technique was unsuccessful.
Treatment of (±)-canalolide A (17) with MCPBA afforded

©2002 International Medical Press

MV inhibition by coumarin analogues

the hydroxyl benzoate 19 (Scheme 5). Conceivably, 19 was
formed via the epoxide intermediate. Under the reaction
conditions, exclusive opening of the epoxide at the benzylic
position was observed. It was assumed that the hydroxyl
group and the benzoate were trans to each other. Further
evidence for this was obtained by the hydrolysis of 19 to
give the 7,8-dihydroxy compound. Thus, hydrolysis of 19
with NaOMe in MeOH yielded the lactone-opened derivative 20 and the corresponding trans-7,8-dihydroxy calanolide A (21). Spectroscopic data of 21 were consistent with
the 7,8-diol structure. The relative stereochemistry of the
diol was assigned as trans as compared with the cis-isomer
18 obtained from stereospecific dihydroxylation of 17 using
OsO4 (vide infra).
Similarly, the MCPBA oxidation of racemic 22 led to
the formation of m-chlorobenzoate 23 (Scheme 6). The
preparation of cis-isomers of 7,8-dihydroxy trans-ketone 24
was successful using RuO2/NaIO4. Both products were
fully characterized by 1H and 13C NMR, IR, mass spectroscopy, and elemental analysis. The assignment of cisconfiguration of the two hydroxyl groups in 24 was based
on the stereospecificity of the dihydroxylation by
RuO2/NaIO4. Treatment of 22 with H2O2 in the presence
of NaOH in methanol and methylene chloride produced a
triol compound 25 with a low yield (13%) and a 65% recovery of the unreacted starting material 22. The formation of
25 might have been involved with a retro-Michael addition
of 22 under the basic conditions to form the intermediate
A which was then epoxided by H2O2 followed by opening
of the epoxide by NaOH (Scheme 6).

Figure 1. Structures of coumarin and pyranocoumarin
analogues tested against measles virus
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Evaluation of coagulation inhibitory activity
Compounds 7, 9 and 18, at 10 or 1 µg/ml, were evaluated
in two assays to measure the anticoagulant properties of
these compounds in normal human plasma. These concentrations bracketed the EC50 values for these compounds.
Sera from five patients were pooled and aliquots were
mixed with each compound and tested in a prothrombin
timing test or in a partial thrombin timing test (aPTT).
The baseline values for the normal plasma was 12.4 s and
for each compound the values ranged from 12.3–12.5 s,
regardless of the dilution of compound tested. In the aPTT
test, the baseline level for the normal plasma was 26.4 s and
the values for the compounds ranged from 26.0 to 26.4 s,
regardless of dilution. Thus, none of the compounds tested
were found to inhibit in vitro coagulation at the concentrations tested.

Results: virology
Primary characterization of antiviral activity
Twenty-two coumarin and pyranocoumarin derivatives
(Figure 1), including the enantiomerically pure
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(+)-calanolide A [(+)-17] and calanolide ketone (+)-22
(Flavin et al., 1996; Khilevich et al., 1996), were tested
against MV strain Chicago. Of the compounds evaluated,
six were considered active as determined by visual assay and
verified by neutral red assay of the same test plate (Table 2).
The EC50 values ranged from 0.2–10 µg/ml by visual assay
and 0.3–5 µg/ml by neutral red assay. Three of those were
propyl coumarin analogues (2a, 7 and 8), two were benzodipyranone with a coumarin nucleus (9 and 10) and one
was a benzotripyranone with a coumarin nucleus (18).
Sixteen of the 22 compounds tested were not active (Table
3), because their selective indices, using both assay methods, were less than 10. Further characterization of the MVinhibitory compounds, by virus yield reduction assay,
revealed that compounds 10 and 18, as measured in virus
yield reduction assay, were the most potent inhibitors of
MV replication (Table 2). This antiviral activity was also
independent of virucidal activity, which was seen only at
high concentrations of compound 10. Of the active drugs
tested, 7 and 8 appeared to be more toxic in actively growing cells; whereas compounds 9 and 18 appeared to be less
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Table 2. Inhibition of strain Chicago-1 measles virus replication in African green monkey kidney (CV-1) cells by
coumarin analogues

Visual assay

Compound
2a
7
8
9
10
18
Ribavirin

Virus
yield
reduction
assay

Neutral red assay

EC50
(µg/ml)

IC50
(µg/ml)

SI

EC50
(µg/ml)

2
0.5
1
0.4
0.2
10
25

90
10
10
6
3
>100
270

45
20
10
15
15
>10
11

1
1
1
0.3
0.6
5
20

IC50
(µg/ml)
100
10
10
10
2
50
196

EC90
(µg/ml)

SI
100
10
10
33
3
10
10

40
1
3
2
0.3
0.3
2

Virucidal
assay
Lowest
virucidal
concentration
(µg/ml)
>100†
>10
>100
ND

40
>10
>1000

Cell
cytotoxicity*

IC50
(µg/ml)
32
1
3
>100
10
41
33

*Cytotoxicity was determined in actively growing cells by neutral red assay.
†Concentrations higher than those shown were not tested.
ND ; not determined.

Table 3. Coumarin analogues weakly selective* or not inhibiting strain Chicago-1 measles virus replication in
African green monkey kidney cells (CV-1)
Visual assay
Compound
1
3b
4
5
6
11
13
14
15
16
(+)-17
20
21
(+)-22
23
25

EC50 (µg/ml)
>100†
2
3
20
>100
10
0.5
20
40
>100
>100
10
10
3
3
20

IC50 (µg/ml)
10
12
7
10
80
20
3
80
20
10
>100
15
> 100
10
7
20

Neutral red assay
SI

EC50 (µg/ml)

0
6
2
0
0
2
6
4
0
0
0
1
>10
3
2
1

>100
3
1
>100
>100
>100
0.6
>100
30
>100
>100
20
100
9
0.4
40

IC50 (µg/ml)
>100
10
6
20
100
>100
2
100
25
20
>100
20
5
14
2
20

SI
0
3
6
0
0
0
3
0
0
0
0
1
0
1
5
0

*Defined as a compound with a selective index of ≤10 µg/ml.
†Concentrations higher than those values shown were not tested.

toxic in these cells (Table 2). Ribavirin inhibited virus as
expected with no virucidal effects seen at the concentrations tested.

Other measles virus strains
Some of the more readily available, active drugs were

16

tested against other measles virus strains (Table 4).
Compounds 7 and 8 appeared to inhibit all strains
equally effectively. However, 10 did not appear to
inhibit strain MO6, an African isolate, although it
did inhibit all other strains with similar potency.
Interestingly, compound 18 was not a potent inhibitor
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Table 4. Inhibition of the replication of various strains of measles virus in African green monkey kidney (CV-1)
cells by selected active compounds
7
Visual
assay
Virus Strain
Bil
CC
Chicago
Edmonston
MO2
MO6
NS2
Sa
TN 1994
X-1108

8
Neutral
red assay

EC50
(µg/ml)

EC50
(µg/ml)

1
1
3
3
4
2
3
0.3
3
2

0.4
2
1
5
3
0.5
1
0.5
ND

6

Visual
assay
EC50
(µg/ml)
0.4
0.3
1
1
0.6
0.6
0.6
0.1
0.1
0.6

10
Neutral
red assay
EC50
(µg/ml)
0.1
1
1
0.4
7
0.6
0.5
0.2
ND

0.3

Visual
assay

18
Neutral
red assay

Visual
assay

EC50
(µg/ml)

EC50
(µg/ml)

EC50
(µg/ml)

0.2
1
0.2
2
4
>100*
3
4
0.1
3

0.1
2
0.6
0.3
1
>100
0.2
0.6

Ribavirin
Neutral
red assay
EC50
(µg/ml)

1
15
10
20
20
10
5
1
3
12

ND

3.6

0.9
4
5
20
50
5
0.5
5
ND

10

Visual
assay

Neutral
red assay

EC50
(µg/ml)

EC50
(µg/ml)

10
80
20
20
20
100
10
20
30
100

2.7
250
25
10
26
100
1
60
ND

130

*Concentrations higher than those shown were not tested.
ND, not determined.

of most of the virus strains used when compared to the
other compounds in Table 4, which correlated with the
results described above using the Chicago strain.

Effects of multiplicity of infection
The effects of various MOIs were determined with 7 (most
readily available) against strain Chicago. The potency of
this compound was slightly MOI-dependent by both visual and NR methods (Table 5). The EC50 concentration rose
slightly as the concentration of virus increased, although by
visual assay a titre was not calculable at the higher concentrations tested. Ribavirin also showed a similar pattern, a
slight increase in the inhibition concentration as the MOI
increased, using both visual and NR assays.

Preliminary mode of action studies
To better understand at which part of the virus replication
cycle these compounds were most efficacious, a timing
assay was done using an MOI as high as possible (MOI =
0.04) with strain Chicago to approach a scenario in which
there is a simultaneous infection of as many cells as possible. Using such a format, two of the drugs (7 and 9) were
evaluated along with ribavirin in a timing assay. The compounds were added at various times before or after virus
infection or near simultaneously as in the typical antiviral
assay. The EC50 values derived from this experiment are
shown in Table 6. For both coumarin analogues, the time of
addition did not appear to affect their potency. However,
ribavirin was somewhat less inhibitory when added at 24 h
post virus exposure than when added simultaneously or at
early times after virus exposure.
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Drug combination studies
It was interesting to determine how one of the coumarin
analogues would interact with ribavirin when used in combination with it in antiviral experiment versus MV. Varying
concentrations of 7 were tested alone and in combination
with varying concentrations of ribavirin. The peaks of
synergism or antagonism, as ascertained by the
MacSynergy (computer program), were used as indicators
of drug interactions. The anti-MV activity of ribavirin was
not augmented by any significant degree when used in

Table 5. Effects of the multiplicity of infection on
the inhibition of measles virus (strain CC) replication
in African green monkey kidney cells (CV-1) by 7 and
ribavirin
7

Ribavirin
EC50

EC50

MOI
0.04
0.02
0.01
0.005
0.002
0.001†
0.0004

Visual assay Neutral red
assay
(µg/ml)
(µg/ml)
>10*
>10
10
10
6
1
1

10
10
6
10
10
6
6

Visual assay Neutral red
assay
(µg/ml)
(µg/ml)
25
20
25
20
20
10
15

25
20
25
20
15
10
15

*Denotes that a concentration greater than indicated was not evaluated.
†Multiplicity of infection (MOI) used in normal antiviral test.
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Table 6. The effects of time of addition of 7 and 9 on measles virus (Chicago) replication in (CV-1) cells
Time of addition
of compound
–1*
0†
1‡
2
4
6
8
24

7
Visual assay
0.5
0.1
0.2
0.5
0.5
0.5
0.5
0.5

Neutral red assay

Visual assay

3
0.1
<0.1§
1
3
3
1
3

0.7
1
0.4
1
1
1
1
2

9
Neutral red assay
2
1
1
0.5
1
0.5
0.5
2

Ribavirin
Visual assay Neutral red assay
10
5
3
10
10
5
4
20

5
2
10
10
5
5
10
20

*Compound was added to the cells 1 h prior to exposure to virus. At time 0, virus was added at a multiplicity of infection=0.04 to the compound-treated cells and incubated with the cells until the assay was ended.
†An equal volume of virus was added to dilutions of compound on cells within 5 min of compound addition to cells.
‡After exposure of cells to virus for one of the time periods (1–24 h) indicated, an appropriate concentration of was added to the virusinfected cells and incubated with those cells until the assay ended.
§Concentrations lower than shown were not tested.

combination with 7 (Figure 2a). This was also verified by
NR assay (data not shown). In contrast, there was some
apparent antagonism detected at the highest concentration
of ribavirin used in combination with most concentrations
of 7 used. The effects on cytotoxicity followed a similar pattern of antagonism, although this amelioration of ribavirin
toxicity was relatively minor (Figure 2b).

Discussion
Coumarin-type compounds have previously been shown to
inhibit tumours and viruses (McKee et al., 1996;
Pengsuparp et al., 1999; Semple et al., 1999). Thus, these
lead compounds have stimulated interest in the synthesis of
more potent, less toxic analogues. This study was part of a
larger project to determine the virus spectrum inhibited by
this set of coumarin analogues. In addition to the evaluation of MV inhibition shown in Tables 2 and 3, the 22
coumarins were also screened against other viruses selected
from the following families: Arenaviridae, Adenoviridae,
Bunyaviridae, Flaviviridae, Orthomyxoviridae (influenza
viruses A and B), Paramyxoviridae (parainfluenza 3 virus
and respiratory syncytial virus) and the Togaviridae. None
of the compounds were active against these viruses, with
exception of 7 which exhibited some activity against rhinoviruses (data not shown). Thus, the results suggest that
most of the compounds shown to be active against MV
appear to be specific inhibitors of MV replication.
When the active analogues were evaluated against other
MV strains, all other strains were also potently inhibited
with the exception of one isolate from Africa, MO6, which
was not sensitive to inhibition by 10 (Table 4). Thus, the
compounds have inhibited all measles viruses tested to
date. The spectrum of viruses strains inhibited and the
potency of the inhibition appeared to be independent of
any particular clade system or genetic grouping system
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developed for MV (Bellini & Rota, 1998; Rota et al., 1998;
Takada et al., 1999).
The mode of action of these compounds remains
unclear. The virucidal studies strongly suggest that the
compounds do not simply degrade the virus when it is
exposed to the analogues. In timing studies, virus was
inhibited at any time the compound (7 or 9) was added,
pre- or postvirus exposure (Table 5). However, because the
MOI (0.01) used may not have statistically achieved a condition in which every cell was exposed to virus simultaneously, it may be that the compounds could have simply prevented the spread of virus by blocking attachment or penetration of any infectious virus released through multiple
cycles of virus replication conducive to a low MOI experiment. The coumarin analogues, as represented by 7, did not
appear to act synergistically when combined with ribavirin
against MV replication; at the highest concentration evaluated, ribavirin seemed to antagonize the inhibition of MV
replication by coumarin 7 when they were used together in
a combination therapy. Taken all together, the results could
suggest that the compounds did not inhibit the same part
of the replication cycle of MV that ribavirin does; for
example, perhaps they do not act as mutagens for viral
RNA (Crotty et al. 2001).
Preliminary analysis of structural anti-MV activity relationship on the 22 compounds tested revealed at least four
characteristics (Figure 1). (1) The unsubstituted or C-substituted 5,7-dihydroxycoumarins such as 1, 4, 5 and 6 were
generally inactive against MV, with compound 4 being
somewhat active (EC50 of 1 mg/ml in neutral red assay). (2)
The O-substituted 5,7-dihydroxycoumarins such as 2a, 7
and 8 were generally active against MV. Compound 2a was
relatively less active but also less toxic. (3) In the benzodipyranone (or chromeno-coumarin) system, 10-C-substitution was detrimental to the anti-MV activity (14 and
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Figure 2. (a) The effects of the combination of (7)
and ribavirin on the replication of MV in African
green monkey kidney cells (CV-1). (b) The cytotoxic
effects of the combination of (7) and ribavirin on
African green monkey kidney cells (CV-1)

(a)

20

20

0

0

20
0

-40

-60

-60

-80

-80

-60

-100

-100

-80

-120

-120

0.032

0.32

0.1

3.2

-40

Antagonism

-100

10

1

0.1

1

-20

-120

0.32

0.0032

0.01

0

0.032

Ribavirin (µg/ml)

3.2

32

-20

-40

10

-20

Synergy

7 (µg/ml)

(b)
0

Synergy

0

0

-10
-10

-10

-20

-20

-30

-30

-40

-40

-50

-50

-20

-30

Antagonism

-40

1
0.32

10

3.2

100

0.32

32

10

32

1

0.01

0.032

0

0.01

Ribavirin (µg/ml)

3.2

320

-50

7 (µg/ml)

25 versus 13). The 9-O-substitution had a critical impact
on the anti-MV activity of benzodipyranone compounds.
For example, the 9-O-unsubstituted compound 13, with a
free OH group, was active against MV but was relatively
toxic as well, with an SI ranging from 3 to 6. The 9-O-acylated derivatives (9 and 10) maintained the anti-MV of 13
but with decreased toxicity. The SI of 9 was increased from
15 to 33. However, the 9-O-sulfonate 11 and the alkylated
analogues 15 and 16 appeared to be detrimental. One may
consider that 13 was the actual biologically active agent
responsible for both the anti-MV activity as well as the toxicity seen. The 9-O-acylated 9 and 10 may have exerted
their anti-MV activity after being hydrolyzed to the active
form 13 during the assay process and these esters may be
less toxic than the parent 13. This hypothesis may be supported by the following observations. First, compound 10
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is more toxic than 9. It may not be surprising considered
that the pivaloyl group in 10 may be easier, compared with
the acetyl group in 9, to be hydrolyzed chemically or enzymatically, resulting in a quicker release of 13 and the toxicity observed, while release of 13 from 9 may be in a slower
and more controlled fashion. Second, when the 9-O-position of 13 is substituted by a non-cleavable group (15 and
16) or by a sulfonyl group which is relatively difficult in
hydrolysis, its anti-MV activity was greatly reduced. (4) For
the benzotripyranone compounds, the hydroxyl group(s) at
the 7- and/or 8- position is essential for anti-MV activity
[18 versus (+)-17, and 23 versus (+)-22]. Furthermore, the
stereochemistry of the 7,8-dihydroxyl groups in the
hydroxylated benzotripyranones may play an important
role in the anti-MV activity. For instance, the cis-dihydroxyl compound 18 is active while the corresponding transisomer 21 is not and neither is 20 with the two hydroxyl
groups being trans to each other and the coumarin ring
open. It is interesting to note that compound 23 is active
against MV even though the hydroxyl and benzoate groups
are trans to each other. However, 23 is relatively toxic
resulting in an SI of only 2 to 5. It is also worth noting that
both 18 and 23 are a diastereomeric mixture containing a
total of four different stereoisomers. One may assume that
the pure form of a stereoisomer should be at least fourfold
more active than 18 or 23 if only one isomer is accounted
for the activity observed. Confirmation of this hypothesis
awaits the separation and test of these stereoisomers, which
is currently under way.
In summary, the coumarin and pyranocoumarin analogues evaluated in this study represent a new class of compounds that have been found to be active against MV. They
appear to be rather specific inhibitors of MV and inhibit all
strains of MV tested to date. Thus, these compounds may
be valuable leads in the development of a potent and selective class of MV inhibitors that could be used in future in
the clinic.
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